Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1515/dmpt-2018-0016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy.
Skelet Muscle
September 2021
Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387, Kraków, Poland.
Background: Duchenne muscular dystrophy (DMD) is an incurable disease, caused by the mutations in the DMD gene, encoding dystrophin, an actin-binding cytoskeletal protein. Lack of functional dystrophin results in muscle weakness, degeneration, and as an outcome cardiac and respiratory failure. As there is still no cure for affected individuals, the pharmacological compounds with the potential to treat or at least attenuate the symptoms of the disease are under constant evaluation.
View Article and Find Full Text PDFEffect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.
Clin Pharmacol Ther
September 2021
Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA.
The association between the c.521T>C variant allele in SLCO1B1 (reference single nucleotide polymorphism (rs)4149056) and simvastatin-induced myotoxicity was discovered over a decade ago; however, whether this relationship represents a class effect is still not fully known. The aim of this study was to investigate the relationship between rs4149056 genotype and statin-induced myotoxicity in patients taking atorvastatin and lovastatin.
View Article and Find Full Text PDFIn patients at high CV risk receiving simvastatin, the Myopathy Risk Score predicted statin-related myopathy.
Ann Intern Med
December 2020
Duke University, Durham, North Carolina, USA (M.D.K., L.K.N.).
Hopewell JC, Offer A, Haynes R, et al. Eur Heart J. 2020;41:3336-42.
View Article and Find Full Text PDFIndependent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom.
Eur Heart J
September 2020
Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, Big Data Institute, University of Oxford, Old Road Campus, Oxford OX3 7LF, UK.
Aims: Statins are widely used to prevent cardiovascular events, but little is known about the impact of different risk factors for statin-related myopathy or their relevance to reports of other types of muscle symptom.
Methods And Results: An observational analysis was undertaken of 171 clinically adjudicated cases of myopathy (defined as unexplained muscle pain or weakness with creatine kinase >10× upper limit of normal) and, separately, of 15 208 cases of other muscle symptoms among 58 390 individuals with vascular disease treated with simvastatin for a mean of 3.4 years.
Simvastatin-related myopathy in shift workers: a report of two cases.
Drug Metab Pers Ther
September 2018
Instituto Politecnico Nacional, CIIDIR-Durango, Academia de Genomica, Durango, Mexico.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!